COVID-19 vaccines developed by Thai researchers undergoing human trials | Inquirer News
Close  

COVID-19 vaccines developed by Thai researchers undergoing human trials

/ 03:13 PM July 05, 2021
thai covid-19 vaccines

The Nation/Asia News Network

BANGKOK — Three Covid-19 vaccines are undergoing human trials while more than 20 are in the research phase, the National Research Council of Thailand and National Vaccine Institute said.

The Thai government’s Covid-19 Information Centre announced on Sunday that combined data from the two institutes revealed more than 20 vaccines are being researched and developed in Thailand, while three have started human trials.

ADVERTISEMENT

The three in human trials stage are:

– ChulaCov19, an MRNA vaccine developed by Chulalongkorn University. It is in the first phase of human trials among 72 candidates. Two doses of the vaccine were given at an interval of 21 days.

FEATURED STORIES

– HXP-GPOVac is an inactivated vaccine jointly developed by the Faculty of Tropical Medicine at Mahidol University and the Government Pharmaceutical Organization. It is in the second phase of human trials with 460 candidates. Two doses of the vaccine were injected at an interval of 28 days.

– Covigen is a DNA vaccine developed by Bionet Asia and Technovalia, which has started its first phase of human trials among 150 candidates. Two doses of the vaccine were injected at an interval of 28 days.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: ChulaCov19, COVID-19 Vaccines, Covigen, Health, human trials, HXP-GPOVac, Thailand
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.